The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus

[Article in English, Chinese]

Lei Liu¹, Zhongzheng Xiang¹, Yi Li², Wei Guo³, Kai Yang⁴, Jun Wang¹, Zhijun Sun⁵, Guoxin Ren³, Jianguo Zhang⁶, Moyi Sun⁷, Wei Ran⁸, Guilin Huang⁹, Zhangui Tang¹⁰, Longjiang Li²

Affiliations

¹ Dept. of Head and Neck Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
² State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
³ Dept. of Oral and Maxillofacial-head and Neck Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, China.
⁴ Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
⁵ Dept. of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
⁶ Dept. of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China.
⁷ Dept. of Oral and Maxillofacial Surgery, Hospital of Stomatology, Air Force Medical University, Xi'an 710032, China.
⁸ Dept. of Oral and Maxillofacial Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
⁹ Dept. of Oral and Maxillofacial Surgery, Stomatological Hospital, Zunyi Medical University, Zunyi 563000, China.
¹⁰ Dept. of Oral and Maxillofacial Surgery, Xiangya School of Stomatology, Central South University, Changsha 410000, China.

PMID: 36416313
PMCID: PMC9763948
DOI: 10.7518/hxkq.2022.06.001

The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus

[Article in English, Chinese]

Lei Liu et al. Hua Xi Kou Qiang Yi Xue Za Zhi. 2022.

. 2022 Dec 1;40(6):619-628.

doi: 10.7518/hxkq.2022.06.001.

Authors

Lei Liu¹, Zhongzheng Xiang¹, Yi Li², Wei Guo³, Kai Yang⁴, Jun Wang¹, Zhijun Sun⁵, Guoxin Ren³, Jianguo Zhang⁶, Moyi Sun⁷, Wei Ran⁸, Guilin Huang⁹, Zhangui Tang¹⁰, Longjiang Li²

Affiliations

¹ Dept. of Head and Neck Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
² State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
³ Dept. of Oral and Maxillofacial-head and Neck Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, China.
⁴ Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
⁵ Dept. of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
⁶ Dept. of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China.
⁷ Dept. of Oral and Maxillofacial Surgery, Hospital of Stomatology, Air Force Medical University, Xi'an 710032, China.
⁸ Dept. of Oral and Maxillofacial Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
⁹ Dept. of Oral and Maxillofacial Surgery, Stomatological Hospital, Zunyi Medical University, Zunyi 563000, China.
¹⁰ Dept. of Oral and Maxillofacial Surgery, Xiangya School of Stomatology, Central South University, Changsha 410000, China.

PMID: 36416313
PMCID: PMC9763948
DOI: 10.7518/hxkq.2022.06.001

Abstract

Immune checkpoint inhibitors (ICIs) present significant efficacy in the treatment of malignant tumors, and they have been approved as the first-line of treatment for various cancers. Pembrolizumab monotherapy or combined with chemotherapy has been recommended by domestic and foreign guidelines for the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma. Although ICIs represent a milestone in the treatment of head and neck squamous cell carcinoma, potential problems still need to be addressed, such as the selection of the efficacy predictors for ICIs, the evaluation of the tumor response to ICIs, and the treatment of immune hyperprogression and immune-related adverse events. Therefore, to form a relatively unified understanding of ICIs treatment for head and neck squamous cell carcinoma, we integrated the clinical experience of multi-disciplinary experts of head and neck cancers on the basis of current clinical hot issues and finally developed this consensus.

Keywords: expert consensus; head and neck squamous cell carcinoma; immune checkpoint inhibitors; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

利益冲突声明：作者声明本文无利益冲突。

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J] CA Cancer J Clin. 2018;68(6):394–424. - PubMed
1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J] CA Cancer J Clin. 2016;66(2):115–132. - PubMed
1. Gupta B, Johnson NW, Kumar N. Global epidemiology of head and neck cancers: a continuing challenge[J] Oncology. 2016;91(1):13–23. - PubMed
1. American Cancer Society. Cancer Facts & Figures 2019[R] Atlanta: American Cancer Society; 2019.
1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J] N Engl J Med. 2008;359(11):1116–1127. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus

Affiliations

The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus

Authors

Affiliations

Abstract

Conflict of interest statement

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical